Author Correction: Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients

Santoru, Maria Laura; Piras, Cristina; Murgia, Antonio; Palmas, Vanessa; Camboni, Tania; Liggi, Sonia; Ibba, Ivan; Lai, Maria Letizia; Orrù, Sandro; Blois, Sylvain; Loizedda, Anna Lisa; Griffin, Julian L.; Usai, Paolo; Caboni, Pierluigi; Atzori, Luigi

doi:10.1038/s41598-018-23330-5

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the prevalence of Faecalibacterium negatively correlated with phenethylamine levels, suggesting a role of this metabolite in the pathogenesis of inflammatory conditions. 5 Furthermore, in RM at 56 weeks of treatment, the baseline level of 3-hydroxybutyric acid at week 0 decreased at 56 weeks of treatment in our study. 3-Hydroxybutyric acid was found to attenuate stress-induced inflammatory responses and increase SCFA production in an in vitro colonic microbial model.…”

Section: Discussionsupporting

confidence: 43%

“…1 Several studies have suggested that the gut microbiota and its metabolites can affect the development and progression of IBD. 2–5 Metabolic alterations [such as those in bile acids and short-chain fatty acids (SCFA)] have been identified in biofluids of patients with UC and Crohn’s disease (CD) in many studies and may provide novel therapeutic solutions. 6,7 Fecal samples can serve as reliable and practical sources to determine the composition of metabolites derived from the gut microbiota.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis

Kim

Shin

Park

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Therapeutic targets for ulcerative colitis (UC) and prediction models of antitumor necrosis factor (TNF) therapy outcomes have not been fully reported. Objective: Investigate the characteristic metabolite and lipid profiles of fecal samples of UC patients before and after adalimumab treatment and develop a prediction model of clinical remission following adalimumab treatment. Design: Prospective, observational, multicenter study was conducted on moderate-to-severe UC patients ( n = 116). Methods: Fecal samples were collected from UC patients at 8 and 56 weeks of adalimumab treatment and from healthy controls (HC, n = 37). Clinical remission was assessed using the Mayo score. Metabolomic and lipidomic analyses were performed using gas chromatography mass spectrometry and nano electrospray ionization mass spectrometry, respectively. Orthogonal partial least squares discriminant analysis was performed to establish a remission prediction model. Results: Fecal metabolites in UC patients markedly differed from those in HC at baseline and were changed similarly to those in HC during treatment; however, lipid profiles did not show these patterns. After treatment, the fecal characteristics of remitters (RM) were closer to those of HC than to those of non-remitters (NRM). At 8 and 56 weeks, amino acid levels in RM were lower than those in NRM and similar to those in HC. After 56 weeks, levels of 3-hydroxybutyrate, lysine, and phenethylamine decreased, and dodecanoate level increased in RM similarly to those in HC. The prediction model of long-term remission in male patients based on lipid biomarkers showed a higher performance than clinical markers. Conclusion: Fecal metabolites in UC patients markedly differ from those in HC, and the levels in RM are changed similarly to those in HC after anti-TNF therapy. Moreover, 3-hydroxybutyrate, lysine, phenethylamine, and dodecanoate are suggested as potential therapeutic targets for UC. A prediction model of long-term remission based on lipid biomarkers may help implement personalized treatment.

show abstract

Section: Discussionsupporting

confidence: 43%

Section: Introductionmentioning

confidence: 99%

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis

Kim

Shin

Park

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Elevated levels of polyamines may be toxic and are associated with several diseases. Cadaverine levels have also been directly associated with Escherichia in Crohn's disease patients, which suggests the presence of intestinal inflammation (22). While their specific roles are largely unknown, they may have a potential role in the occurrence and development of BMJ.…”

Section: Discussionmentioning

confidence: 99%

Changes in Intestinal Flora and Metabolites in Neonates With Breast Milk Jaundice

Shen

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

Background: Breast milk jaundice (BMJ) is the first cause of neonatal jaundice; however, its underlying mechanism is yet to be deciphered. We conducted a study to investigate intestinal flora in neonates with BMJ and used metabolomics to decipher the possible mechanisms by which intestinal flora induces jaundice. Methods: Microbiota collected from the feces of BMJ patients and jaundice-free breastfeeding newborns was used for 16S rRNA sequencing. In addition, differences in fecal metabolites were analyzed using gas chromatography mass spectrometry (GC/MS). The relationship between intestinal microbiota and the differences in fecal metabolites was then analyzed. Results: There was no significant difference in the richness and diversity of intestinal flora between BMJ and the control group; however, there were differences in the structure. At the phylum level, the relative abundance of Firmicutes was higher in the control group compared to the BMJ group, whereas Proteobacteria was higher in the infants with BMJ. Additionally, at the genus level, the relative abundance of Haemophilus was higher in the control group, whereas the relative abundances of Escherichia, Morganella, and Rothia were lower. More remarkably, the major differences in metabolites between the two groups were glyceric acid, succinic acid, and phenylalanine. Additionally, the abundance of Escherichia was positively correlated with succinic acid and cadaverine levels. Conclusions: The intestinal flora colonization status in BMJ patients is immature. This study reports for the first time that the study of intestinal flora, especially Escherichia, plays an important role in BMJ, and found that it may be associated with the regulation of succinic acid metabolic pathways.

show abstract

“…Una dieta alta en AG saturados se ha asociado con una reducción en la diversidad de la MI (Sonnenburg, Tremaroli, Kovatcheva, Cani & Backhed, 2016) con aumento de bacterias patógenas (Fava et al, 2013), desarrollo de inflamación intestinal (Devkota et al, 2012), resistencia a la insulina e inflamación sistémica de bajo grado . Por otro lado, los efectos de los ácidos grasos poliinsaturados (AGPI) dependen del tipo de AGPI, ya que los AGPI ω-6 pueden provocar disbiosis asociada con inflamación intestinal (Prossomariti et al, 2017) y obesidad (Kaliannan, Wang, Li, Kim & Kang, 2015), mientras que los AGPI ω-3 pueden revertir la disbiosis y promover una microbota saludable (Santoru et al, 2017), además de servir como precursores de sustancias antiinflamatorias capaces de mantener la integridad del epitelio, por lo que están asociados con la prevención o tratamiento de ciertas enfermedades (Li et al, 2008).…”

Section: Oligosacáridos De La Leche Materna (Hmo)unclassified

Prebióticos y microbiota: Factores clave en el síndrome metabólico

et al. 2022

View full text Add to dashboard Cite

El síndrome metabólico (SMet) es un problema complejo de salud pública mundial, enfermedades relacionadas con él son causa de muerte que en el año 2020 fue del 43%. El tratamiento y la prevención del SMet sin el uso de fármacos tiene un impacto significativo al abordar el problema de forma integral. Esencialmente con cambios en el estilo de vida, al modificar la dieta incluyendo compuestos bioactivos que favorecen a la microbiota intestinal (MI) y un aumento de la actividad física. Debido al papel de la (MI) en la patogénesis del SMet, en los últimos años se han incorporado a la dieta probióticos y prebióticos individualmente o mezclados con alimentos o suplementos. La presente revisión define el papel de los prebióticos en la modificación de la microbiota para el tratamiento y la prevención de este padecimiento.

show abstract

Author Correction: Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients

Abstract: A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

Cited by 7 publications

References 0 publications

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis

Changes in Intestinal Flora and Metabolites in Neonates With Breast Milk Jaundice

Prebióticos y microbiota: Factores clave en el síndrome metabólico

Contact Info

Product

Resources

About